Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
October 23, 2019 02:00 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with...
Biofrontera shows robust growth during first six months of 2019
August 27, 2019 02:15 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results
August 14, 2019 05:30 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera provides update on Cutanea integration
August 05, 2019 09:00 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Swissmedic approves Ameluz® in combination with daylight photodynamic therapy in Switzerland
October 01, 2018 09:08 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today that Swissmedic, the...
Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma
September 26, 2018 03:15 ET
|
Biofrontera AG
Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...